Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients
Stopped Study was terminated early for strategic reasons. Only Part I of the study was completed.
Conditions
- Pulmonary Arterial Hypertension
Interventions
Sponsor
Novartis Pharmaceuticals